142 related articles for article (PubMed ID: 35665971)
1. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
Eur J Cancer; 2022 Jul; 169():1-9. PubMed ID: 35489301
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
[TBL] [Abstract][Full Text] [Related]
4. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
[TBL] [Abstract][Full Text] [Related]
5. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract][Full Text] [Related]
6. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
[TBL] [Abstract][Full Text] [Related]
7. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
[TBL] [Abstract][Full Text] [Related]
8. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
Lu X; Yan S; Koral KA; Chen Z
Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
[No Abstract] [Full Text] [Related]
9. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
[TBL] [Abstract][Full Text] [Related]
10. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis.
Cai T; Cheng Y; Du Y; Tan P; Li T; Chen Y; Gao L; Fu W
Oncol Lett; 2023 Jun; 25(6):273. PubMed ID: 37216159
[TBL] [Abstract][Full Text] [Related]
12. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
13. Surufatinib: First Approval.
Syed YY
Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
[TBL] [Abstract][Full Text] [Related]
14. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
Xu J
Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
[TBL] [Abstract][Full Text] [Related]
15. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
Zhang J; Zhu H; Shen L; Li J; Zhang X; Bai C; Zhou Z; Yu X; Li Z; Li E; Yuan X; Lou W; Chi Y; Xu N; Yin Y; Bai Y; Zhang T; Xiu D; Chen J; Qin S; Wang X; Yang Y; Shi H; Luo X; Fan S; Su W; Lu M; Xu J
Chin J Cancer Res; 2023 Oct; 35(5):526-535. PubMed ID: 37969958
[TBL] [Abstract][Full Text] [Related]
16. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Xu J; Bai Y; Sun H; Bai C; Jia R; Li Y; Zhang W; Liu L; Huang C; Guan M; Zhou J; Su W
Cancer; 2021 Nov; 127(21):3975-3984. PubMed ID: 34355801
[TBL] [Abstract][Full Text] [Related]
17. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
19. Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans.
Li K; Ma S; Miao L; Fan S; Pan B; Zhang W; Su W; Xiong Y; Gu Z; Guo L; Sai Y
Curr Drug Metab; 2020; 21(5):357-367. PubMed ID: 32407271
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review.
Wang X; Hu S; Su F; Lin J; Duan J; Tan H; Tan H
Ann Transl Med; 2022 Nov; 10(22):1254. PubMed ID: 36544653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
